D. Boral Capital has downgraded its rating for Plus Therapeutics (PSTV) to Hold.

Plus Therapeutics has announced a reverse stock split, a corporate action to reduce the number of its outstanding shares.

Plus Therapeutics reported a GAAP EPS of -$0.29, beating estimates by $0.01, and revenue of $5.21 million, surpassing expectations by $0.14 million.